Evidence map›Paper›PMID 30904940›Full record

ArticlePsychopharmacology2019

2-Aminoindan and its ring-substituted derivatives interact with plasma membrane monoamine transporters and α

Adam L Halberstadt, Simon D Brandt, Donna Walther, Michael H Baumann

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Psychopharmacology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 48% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 2 countries.

Adam L HalberstadtDepartment of Psychiatry, University of California San Diego, 9500 Gilman Drive, La Jolla, CA, 92093-0804, USA. ahalberstadt@ucsd.edu.
Simon D BrandtSchool of Pharmacy and Biomolecular Sciences, Liverpool John Moores University, Byrom Street, Liverpool, L3 3AF, UK.
Donna WaltherDesigner Drug Research Unit, Intramural Research Program, National Institute on Drug Abuse, National Institutes of Health, Baltimore, MD, 21224, USA.
Michael H BaumannDesigner Drug Research Unit, Intramural Research Program, National Institute on Drug Abuse, National Institutes of Health, Baltimore, MD, 21224, USA.
National Institute on Drug Abuse · USLiverpool John Moores University · GBUniversity of California, San Diego · US

Funding

Preclinical medication development for stimulant use disorderZIADA000522 · NIDA · NATIONAL INSTITUTE ON DRUG ABUSE · PI BAUMANN, MICHAEL · 2009 to 2025
$8.9M
The Next Generation of Hallucinogens: A New Class of Synthetic Psychoactive DrugsR01DA041336 · NIDA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI HALBERSTADT, ADAM L. · 2017 to 2020
$1.4M
IMPROVING HEALTH CARE UTILIZATION IN HIV+ DRUG USERSK23DA000523 · NIDA · JOHNS HOPKINS UNIVERSITY · PI GEBO, KELLY A · 2001 to 2005
$794k
Studies on MDMA and Related CompoundsZ01DA000523 · NIDA · NATIONAL INSTITUTE ON DRUG ABUSE · PI ROTHMAN, RICHARD · 2008 to 2008
$199k
Intramural NIH HHS Z01 DA000523NIDA NIH HHS K23 DA000523NIDA NIH HHS R01 DA041336
6 · The paper itself

Abstract

rationaleOver the last decade, many new psychostimulant analogues have appeared on the recreational drug market and most are derivatives of amphetamine or cathinone. Another class of designer drugs is derived from the 2-aminoindan structural template. Several members of this class, including the parent compound 2-aminoindan (2-AI), have been sold as designer drugs. Another aminoindan derivative, 5-methoxy-2-aminoindan (5-MeO-AI or MEAI), is the active ingredient in a product marketed online as an alcohol substitute.

methodsHere, we tested 2-AI and its ring-substituted derivatives 5-MeO-AI, 5-methoxy-6-methyl-2-aminoindan (MMAI), and 5,6-methylenedioxy-2-aminoindan (MDAI) for their abilities to interact with plasma membrane monoamine transporters for dopamine (DAT), norepinephrine (NET) and serotonin (SERT). We also compared the binding affinities of the aminoindans at 29 receptor and transporter binding sites.

results2-AI was a selective substrate for NET and DAT. Ring substitution increased potency at SERT while reducing potency at DAT and NET. MDAI was moderately selective for SERT and NET, with tenfold weaker effects on DAT. 5-MeO-AI exhibited some selectivity for SERT, having sixfold lower potency at NET and 20-fold lower potency at DAT. MMAI was highly selective for SERT, with 100-fold lower potency at NET and DAT. The aminoindans had relatively high affinity for α

conclusions2-AI is predicted to have (+)-amphetamine-like effects and abuse potential whereas the ring-substituted derivatives may produce 3,4-methylenedioxymethamphetamine (MDMA)-like effects but with less abuse liability.

Indexed as

AmphetamineAnimalsCell MembraneDopamineDopamine Plasma Membrane Transport ProteinsHumansIndansMaleNorepinephrineNorepinephrine Plasma Membrane Transport ProteinsProtein BindingRatsRats, Sprague-DawleyReceptors, Adrenergic, alpha-2SerotoninSerotonin Plasma Membrane Transport Proteins2-aminoindanAmphetamineDopamineDopamine Plasma Membrane Transport ProteinsIndansNorepinephrineNorepinephrine Plasma Membrane Transport ProteinsReceptors, Adrenergic, alpha-2SerotoninSerotonin Plasma Membrane Transport ProteinsVesicular Monoamine Transport ProteinsAnalgesiaBindingDopamineMEAINorepinephrineSerotoninStimulantSynaptosomes

Identifiers

PMID30904940
PMCPMC6848746
OpenAlexW2941711387

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.